S719
Clinical – Lower GI
ESTRO 2026
using the EORTC QLQ-C30 and the anal cancer–specific QLQ-ANL27 questionnaires. QLQ-C30 results were compared with age- and sex-matched Italian reference data (Pilz et al., 2022), and correlations with patient-, tumor-, and treatment-related variables were analyzed. Results: Median age was 62 years (range 34–83), and 82% were female. Median follow-up was 51 months.Five-year overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and colostomy-free survival (CFS) were 88.2%, 84.5%, 89.0%, and 97.3%, respectively. Grade ≥ 3 late GI toxicity occurred in 6.7%. Compared with the Italian reference population, both sexes reported significantly higher global QoL (men p = 0.002; women p = 0.001) and similar or superior functional scores, while diarrhea was worse in women (p = 0.0008). In the QLQ-ANL27, younger women (<70 years) and patients with late GI toxicity reported poorer sexual function (p = 0.02) and higher bowel symptom burden, including bowel symptoms (p < 0.001), toileting dependence (p < 0.001), cleaning (p < 0.001), and activity limitation (p = 0.01).
Conclusion: Compared with age-matched Italian controls, PROACT survivors demonstrated higher global QoL and preserved functional recovery after IMRT-based CRT. However, younger women and those with late GI toxicity experienced persistent bowel and sexual disturbances, underscoring the need for targeted supportive interventions and systematic PROM integration in anal cancer survivorship care. References: M. J. Pilz et al., “EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals,” BMC Public Health, vol. 22, no. 1, Dec. 2022, doi: 10.1186/s12889- 022-13211-y. Keywords: QUALITY OF LIFE, PATIENT REPORTED OUTCOMES
Made with FlippingBook - Share PDF online